XML 72 R40.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
Components of Income Tax Expense

The components of income tax expense are as follows:

 

 

 

Years Ended December 31,

 

 

 

2016

 

 

2015

 

Current:

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

State

 

 

10,118

 

 

 

10,189

 

Total current income tax expense

 

$

10,118

 

 

$

10,189

 

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

State

 

 

 

 

 

 

Total deferred income tax expense

 

$

 

 

$

 

Total income tax expense

 

$

10,118

 

 

$

10,189

 

 

Schedule of Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes

 

The Company’s actual income tax expense for the years 2016 and 2015 differ from the expected amount computed by applying the statutory federal income tax rate of 34% to loss before income taxes as follows:

 

 

 

Years Ended December 31,

 

 

 

2016

 

 

2015

 

Computed tax (benefit) at 34%

 

$

(8,850,007

)

 

$

(7,271,785

)

State taxes, net of federal benefit

 

 

(462,609

)

 

 

(918,079

)

Stock-based compensation

 

 

210,367

 

 

 

102,699

 

Expiring state net operating loss ("NOL") carryforwards

 

 

94,962

 

 

 

(20,086

)

Return to provision

 

 

248,263

 

 

 

(27,934

)

Other

 

 

25,718

 

 

 

44,679

 

Research and development tax credit - state

 

 

(453,071

)

 

 

(300,213

)

Research and development tax credit - federal

 

 

(341,785

)

 

 

(342,681

)

Change in valuation reserve

 

 

9,538,280

 

 

 

8,743,589

 

 

 

$

10,118

 

 

$

10,189

 

 

Schedule of Deferred Tax Assets and Liabilities

 

Deferred tax assets and liabilities comprise the following:

 

 

 

Years Ended December 31,

 

 

 

2016

 

 

2015

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

37,114,445

 

 

$

28,795,562

 

Research and development credits

 

 

2,132,050

 

 

 

1,435,314

 

Deferred revenue

 

 

177,683

 

 

 

17,396

 

Inventory reserve

 

 

99,583

 

 

 

104,182

 

Fixed assets and intangibles

 

 

193,833

 

 

 

50,128

 

Change in fair value of warrant liability

 

 

 

 

 

111,993

 

Accrued NuvoGen liability

 

 

3,176,449

 

 

 

3,282,756

 

Capitalized research and development

 

 

 

 

 

27,583

 

Accrued expense

 

 

351,505

 

 

 

 

Other

 

 

233,438

 

 

 

115,792

 

 

 

 

43,478,986

 

 

 

33,940,706

 

Valuation allowance

 

 

(43,478,986

)

 

 

(33,940,706

)

Deferred tax asset, net

 

$

 

 

$

 

 

Summary of Federal Net Operating Loss Carryforwards

The Company’s federal NOL carryforwards have the following expiration dates:

 

 

Year of Expiration

 

2016 Bonus

Amount

 

Federal NOL carryforwards

 

 

 

 

 

 

 

 

2021

 

$

211,806

 

 

 

2023

 

 

1,635,651

 

 

 

2024

 

 

1,217,290

 

 

 

2025

 

 

1,409,498

 

 

 

2026

 

 

1,175,594

 

 

 

2027

 

 

1,676,458

 

 

 

2028

 

 

3,037,785

 

 

 

2029

 

 

3,753,314

 

 

 

2030

 

 

623,235

 

 

 

2031

 

 

5,435,312

 

 

 

2032

 

 

10,913,787

 

 

 

2033

 

 

12,095,966

 

 

 

2034

 

 

14,190,409

 

 

 

2035

 

 

21,079,240

 

 

 

2036

 

 

23,706,988

 

 

 

 

 

$

102,162,333